Koo, from memory, my understanding was the .6% plaque regression target was chosen for the 6 month ASSURE trial because .6% is (I was told) the average annual rate of plaque progression in those with CAD.  In other words the goal of the trial was to remove a years worth of plaque accumulation in 6 months in a sick group.  The reason RVX was so excited to see the Apabetalone + rosuvastatin cohort have a statistically significant PAV reduction of 1.43% was that they had on average removed over 2 years of average plaque accumulation in the 6 month trial.